Bringing the Oncology Community Together

Dr. Dreicer on Sequencing MDV3100 and Abiraterone

Robert Dreicer, MD, MS
Published Online: Wednesday, April 18, 2012
Robert Dreicer, MD, MS, chairman of the Department of Solid Tumor Oncology at the Taussig Cancer Institute at the Cleveland Clinic, discusses the sequencing of MDV3100, an androgen receptor antagonist, and abiraterone acetate, an inhibitor of androgen biosynthesis, for patients with castration-resistant prostate cancer.

The MDV3100 data from the AFFIRM trial showed a significant prolongation in survival and a reduced risk of death. Dreicer expects this information will lead to an initial FDA approval in the post-chemotherapy setting.

Data recently released for abiraterone acetate from the COU-AA-302 study suggest this agent may be effective when given before chemotherapy. If this agent were moved to the pre-chemotherapy space the sequencing order would likely be abiraterone acetate, chemotherapy, followed by MDV3100.

If later data suggest MDV3100 can move prior to chemotherapy there will be a larger discussion on sequencing. Dreicer expects the primary discussion points to be whether MDV31000 and abiraterone acetate should be used in combination or absolute sequence.

Dreicer expects a short initial period where the optimal sequence may not be known, but eventually there will be greater insight into the sequencing of these therapies.

Related Articles
Adding ADT to RT Reduces Risk of Progression in Localized Prostate Cancer
Patients with localized prostate cancer at intermediate or high risk for progression experience better outcomes when 6 months of androgen deprivation therapy is added to standard radiotherapy.
Pretreatment Genetic Test Predicts Recurrence in Prostate Cancer
A novel 100-locus DNA signature obtained from pretreatment biopsies accurately classified 75% of patients with untreated prostate cancer as low- or high-risk.
Immunotherapy Biomarkers and Combinations Needed in CRPC: An Interview With Padmanee Sharma, MD, PhD
An interview with Padmanee Sharma, MD, PhD, on the evolving field of immunotherapy for patients with castration-resistant prostate cancer.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.